Innovus Pharmaceuticals, Inc.
8845 Rehco Road
14 articles with Innovus Pharmaceuticals, Inc.
Preliminary Quarterly Revenue Increase of 47-51% and Comparable 2017 Second Quarter Increase of 330-340% and Fiscal Year 2018 Net Revenue Annual Guidance Adjusted Upwards to at Least $22 Million
SECFilings.com announces the publication of an article covering Innovus Pharmaceuticals Inc.
AllerVarx™ is the Ninth Innovus Pharma Product Launched in Canada to Date
Innovus Pharma Announces the Approval of Its Product ProstaGorx™ in Canada for Benign Prostatic Hyperplasia (“BPH”)
Innovus Pharmaceuticals, Inc. announced the approval by Health Canada of its product ProstaGorx™ as a Natural Health Product (NPN #80085717) for the relief of urologic symptoms.
Innovus Pharmaceuticals, Inc. announced that Dr. Bassam Damaj, its President and Chief Executive Officer, will speak at the 8th Annual LD Micro Invitational Conference.
Innovus Pharmaceuticals, Inc. announced that the Company will release its March 31, 2018 first quarter financial results on Monday, May 14, 2018.
Xyralid®, a Lidocaine-based Cream for the Relief of Pain and Symptoms Caused by Hemorrhoids, is the Sixth Innovus Pharma Product launched in Canada to Date
Innovus Pharma Expands its Senior Management with the Addition of Ryan Selhorn, CPA, as its Vice President, Chief Financial Officer
Industry Veteran to Lead Company’s Financial and Accounting Operations into its Expanding Revenue Growth Stage
Innovus Pharma Announces U.S. Food and Drug Administration Clearance of its GlucoGorx™ Glucose Monitoring Device Test Kit
Innovus Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has cleared the Company’s GlucoGorx™ Glucose Monitoring Test Kit that includes a glucose meter, test strips and lancet device (“GlucoGorx™ Kit”) under the 510(k) filing of its manufacturing partner, ACON Laboratories, Inc. (“ACON”) Innovus Pharma will offer the GlucoGorx™ Kit.
Acerus had previously planned for the Canadian launch of URIVARX® in the second half of 2018, but the Company has arranged for the product to be available in Canada via the Innovus supply chain.
Innovus Pharmaceuticals Reports Record Annual Revenue for Fiscal 2017 of $8.8 Million, Preliminary Q1 2018 Revenue of $4.3 Million to $4.4 Million and Expects to Exit 2018 Profitable
Year over Year Revenue Increase of 83% with Reduction in Net Loss of 53% in 2017 and Fiscal Year 2018 Net Revenue Annual Run Rate of At Least $18 million
Innovus Pharma’s AllerVarx™ Receives Commercial Approval by Health Canada for the Reduction in Symptoms of Seasonal Allergic Rhinitis
AllerVarx™ is the Eighth Innovus Pharma Product approved in Canada to date
New Website Features its Robust Beyond Human® Sales & Marketing Platform
Innovus Pharma Announces the Complete Repayment in Cash of its Financial Obligations from its Acquisition of its Beyond Human® Assets
Payoff in Cash of Outstanding Secured Promissory Note with SBI Investments, LLC also Releases Lien on Company’s Beyond Human® Assets and the Related Revenues